Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) are both among the largest biopharmaceutical businesses in the world, but their growth prospects aren't exactly the same. Nonetheless, the pair handily ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.

Eli Lilly (NYSE:LLY) saw its market cap spike 36.1% during Q2, making it the biggest gainer amongst the top 20 biopharma companies in the world, while AbbVie (ABBV) experienced the largest drop ...

Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.

While this adds competition to a market currently controlled by Eli Lilly LLY -2.84% and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding ...